|Title:||Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries||Authors:||Garland, S M
Ngan, H Y S
Yang, Y C
Cheung, T H
Kim, S C
Ellison, M C
Han, S R
|Keywords:||9vHPV; Asia; cervical cancer; human papillomavirus; vaccine||Issue Date:||5-Jun-2018||Publisher:||OXFORD UNIV PRESS INC||Source:||The Journal of infectious diseases||Abstract:||
A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, and Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16-26 years; NCT00543543; Study 001); and an immunogenicity study (girls and boys aged 9-15 years; NCT00943722; Study 002).
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.